NASDAQ:IMRX Immuneering Q2 2024 Earnings Report $3.50 -0.14 (-3.72%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Immuneering EPS ResultsActual EPS-$0.47Consensus EPS -$0.52Beat/MissBeat by +$0.05One Year Ago EPSN/AImmuneering Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuneering Announcement DetailsQuarterQ2 2024Date8/6/2024TimeTASConference Call DateTuesday, August 6, 2024Conference Call Time4:00PM ETUpcoming EarningsImmuneering's Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Monday, August 4, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immuneering Earnings HeadlinesImmuneering Corporation Rings the Closing BellJuly 16, 2025 | nasdaq.comImmuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate AtebimetinibJuly 9, 2025 | globenewswire.comTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.July 31 at 2:00 AM | Crypto 101 Media (Ad)Immuneering (IMRX) chief people officer Neufeld buys $2498 in stockJuly 8, 2025 | investing.comWe're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn RateJune 20, 2025 | finance.yahoo.comPre-Market Most Active for Jun 17, 2025 : IMRX, TSLL, VERV, RUN, SQQQ, TQQQ, KO, CRCL, DIS, QBTS, BBAI, NIOJune 19, 2025 | nasdaq.comSee More Immuneering Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email. Email Address About ImmuneeringImmuneering (NASDAQ:IMRX), a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.View Immuneering ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?Deckers Stock Recovers on Strong Earnings—More Upside Ahead?3 Reasons Tesla's Post-Earnings Hangover Looks Like a Buy Upcoming Earnings Linde (8/1/2025)Regeneron Pharmaceuticals (8/1/2025)Ares Management (8/1/2025)Colgate-Palmolive (8/1/2025)Chevron (8/1/2025)Enbridge (8/1/2025)W.W. Grainger (8/1/2025)Southern Copper (8/1/2025)Exxon Mobil (8/1/2025)Axon Enterprise (8/4/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
